Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early discharge after paediatric liver biopsy: A prospective observational study.

Journal of pediatric gastroenterology and nutrition·2026

Same author

Acute intoxication and trauma severity in emergency department patients: a systematic review.

BMC emergency medicine·2026

Same author

Remifentanil Versus Rocuronium for Optimising Video Laryngoscopy Assisted Tracheal Intubation-The ROCVIDEO Trial Protocol.

Acta anaesthesiologica Scandinavica·2026

Same author

ICU Clinicians' View on Platelet Transfusion Thresholds for a Future Trial-Protocol for an International Survey.

Acta anaesthesiologica Scandinavica·2026

Same author

Neuromuscular Monitoring of Rocuronium 0.6 mg/kg in Children Aged 3-24 Months With Electromyography and Acceleromyography: An Observational Study.

Paediatric anaesthesia·2026

Same author

Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding.

The Cochrane database of systematic reviews·2026

Search research articles

Related Experiment Video

Updated: May 8, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Fibrinogen concentrate in bleeding patients.

Anne Wikkelsø¹, Jens Lunde, Mathias Johansen

¹Department of Anaesthesiology, University of Copenhagen Herlev Hospital, Herlev, Denmark.

The Cochrane Database of Systematic Reviews

|August 30, 2013

Summary

Fibrinogen concentrate may reduce blood transfusions in surgery patients, but evidence is limited. More research is needed to confirm benefits and safety for bleeding conditions.

More Related Videos

Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis

Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis

Published on: April 29, 2007

Related Experiment Videos

Last Updated: May 8, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis

Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis

Published on: April 29, 2007

Area of Science:

Hematology
Clinical Trials
Evidence-Based Medicine

Background:

Hypofibrinogenaemia increases patient morbidity and mortality.
Optimal fibrinogen treatment levels and sources remain debated.
Fibrinogen concentrate use is rising, but evidence on its efficacy and safety is lacking.

Purpose of the Study:

To assess the benefits and harms of fibrinogen concentrate versus placebo or usual care in bleeding patients.

Main Methods:

Systematic review of randomized controlled trials (RCTs) from multiple databases.
Included bleeding patients (excluding neonates and hereditary disorders).
Primary outcome: all-cause mortality; secondary outcomes: transfusion requirements and adverse events.

Main Results:

Six low-quality RCTs (248 participants) were included; none had low risk of bias.
Fibrinogen concentrate showed a trend towards reduced mortality (not statistically significant).
Significantly reduced allogenic transfusions (RR 0.47, 95% CI 0.31-0.72) but no effect on adverse events.

Conclusions:

Fibrinogen concentrate may reduce transfusion needs in elective surgery but trials are underpowered and high risk of bias.
Evidence is weak, particularly for acute/severe bleeding; data on mortality and harm are lacking.
Urgent, high-quality research is needed to establish the role of fibrinogen concentrate in managing bleeding patients.